Clinical trials: Chronic Hepatitis, B Virus
Hepatitis B, HIV Infections
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral…
- Trial name
- NCT05551273
- Testing
- Selgantolimod
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study
This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treated patients with chronic hepatitis B
- Trial name
- MAFLD-HBV 1 (NCT05708560)
- Where
- 3 sites in Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
Chronic Hepatitis B
A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B
This study is a multi-center, randomized, prospective open-label study to assess the efficacy and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in interferon-naïve chronic hepatitis B patients with…
- Trial name
- NCT02332473
- Testing
- Ypeginterferon alfa-2b, Granulocyte-macrophage colony stimulating factor
- Where
- 12 sites in China
- Volunteers
- 110 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Liver Fibrosis
A Nomogram for Evaluating Significant Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection
Liver fibrosis is the key step for progression to cirrhosis and liver cancer in patients with chronic hepatitis B (CHB). It is crucial to identify significant liver fibrosis in the treatment of CHB patients.
- Trial name
- NCT05560503
- Volunteers
- 259 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Hepatitis
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
The current study is a prospective, randomized, open, multi-center investigation. The aim of the study is to investigate whether the HBeAg seroconversion rate can be improved if applying combination therapy in HBeAg positive CHB…
- Trial name
- NCT03013556
- Testing
- Group A, TDF, Group B:TDF then TDF and Peginterferon alfa-2a, Group C:TDF and Peginterferon alfa-2a then TDF
- Where
- 8 sites in China
- Volunteers
- 180 people
- Sponsor
- Ruijin Hospital
Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
- Trial name
- NCT05853718
- Testing
- Tenofovir Alafenamide Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Hangzhou
Chronic Hepatitis b
The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.
In Taiwan, non-cirrhosis CHB patients with mildly elevated ALT are not candidates for antiviral treatment under Taiwan NIH reimbursement criteria.
- Trial name
- NCT04674423
- Testing
- Tenofovir Alafenamide
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Cheng-Kung University Hospital
The Difficult-to-treat Chronic Hepatitis B
A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy
Antiviral resistance remains an important issue for long-term NA therapy. For lamivudine (LAM), the rtM204V/I and rtL180M mutations occur in more than 70% after 5 years of therapy.
- Trial name
- NCT02019966
- Where
- South Korea
- Volunteers
- 1,020 people
- Sponsor
- Yonsei University
Chronic Hepatitis B
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.
- Trial name
- NCT03585322
- Testing
- APG-1387 for Injection
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Ascentage Pharma Group Inc.
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Acute-on-Chronic Liver Failure, Hepatitis B, Chronic
Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic
HBV-related acute-on-chronic liver failure (HBV-ACLF) deteriorates rapidly with a high short-term mortality. Early identification and accurate prognostic prediction was critical to improve survival rate.
- Trial name
- NCT03977857
- Where
- China
- Volunteers
- 486 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis B
A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B…
- Trial name
- NCT02569372
- Testing
- GC1102
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Chronic Hepatitis B, Chronic Hepatitis D
Lamivudine for Chronic Hepatitis B
Chronic hepatitis B is a disease of the liver caused by the hepatitis B virus. It affects nearly 1 million Americans. Approximately 25% of patients with chronic hepatitis B will develop liver cirrhosis and 5% of patients will…
- Conditions
- Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
- Trial name
- NCT00001457
- Testing
- Lamivudine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604212
- Testing
- ARC-520, entecavir, antihistamine
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B, Chronic
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB)…
- Trial name
- NCT01023230
- Testing
- DV-601, Entecavir
- Where
- 4 sites in Poland
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Chronic Hepatitis B Virus
T-cell Dysfunction in Chronic HBV Infection
Chronic hepatitis B (CHB) infection remains an important public health with more than 240 million people chronically infected despite the existence of an effective vaccine.
- Trial name
- VHB-Roche (NCT05099458)
- Testing
- Additional blood sampling (100 ml)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Hepatitis b, Hepatic Carcinoma
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
The current study is a prospective, randomized, open, multi-center investigation. The aim of current study is to investigate whether the Recurrence-free Survival Rate (RFS）of the hepatitis B related -hepatocellular carcinoma…
- Trial name
- NCT03253250
- Testing
- ETV；TDF；ADV, Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis B
The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia
Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of HCC, which brings huge economic burden and life threat to our people. 84% - 92% of HCC in China is related to chronic HBV infection.
- Trial name
- NCT05357235
- Testing
- PEG-IFN
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
- Trial name
- NCT02738008
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 6 sites in China, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Arrowhead Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.